Phase 2 failure for Innate Pharma leukaemia drug

pharmafile | February 6, 2017 | News story | Research and Development, Sales and Marketing Innate Pharma, leukaemia, lirilumab 

Lirilumab, Innate Pharma’s acute myeloid leukaemia (AML) treatment, has failed to meet its primary end point in a recent Phase 2, the company has just announced.

Lirilumab was trialled for its efficacy as a single agent maintenance treatment for elderly patients with (AML), tested across two study arms testing the drug as a single agent at various different doses and treatment intervals; one of these arms was discontinued following intervention from the Data and Safety Monitoring Board (DSMB) over concerns it had become impossible to reach its endpoint. Over the course of the trial, the drug failed to show any significant capacity to improve leukaemia-free survival (LFS) over placebo.

Despite the failure, the company is confident in its development of a range of lirilumab applications through combination treatments.

“Although we knew that this setting was challenging, we are disappointed by the results of the EffiKIR study and will investigate further to better understand the data in its entirety,” commented Innate Pharma CMO Pierre Dodion. “However, EffiKIR is only one of seven studies currently investigating lirilumab. Lirilumab is tested in a broad and comprehensive combination program in multiple indications and we saw encouraging early efficacy signals of lirilumab in combination with nivolumab at the 2016 SITC meeting. We are looking forward to the next data sets as well as the next steps for the program in 2017.”

Matt Fellows

Related Content

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase …


Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …

Latest content